Ware J. Anthony 4

What Happened

• Ware J. Anthony, a director of First Tracks Biotherapeutics, had 6,030 restricted stock units (RSUs) vest on June 15, 2026. The Form 4 shows 6,030 shares acquired at $0.00 and a corresponding derivative conversion/disposition of 6,030 shares at $0.00. No cash was paid — this reflects settlement of awards, not an open‑market purchase or sale.

Key Details

• Transaction date: June 15, 2026; Form 4 filed June 17, 2026 (timely filing).
• Reported entries: 6,030 shares acquired @ $0.00; 6,030 shares disposed (derivative) @ $0.00.
• Footnotes: F1 — each RSU converts to 1 share for no consideration; F2 — 100% of the RSUs vested on June 15, 2026, subject to continued service.
• Shares owned after the transaction: not disclosed in the provided filing data.
• Transaction code M indicates exercise/conversion of a derivative instrument (here, RSU settlement).

Context

• This transaction is vesting/settlement of compensation (RSUs) rather than a cash purchase or a market sale; such awards are routine executive/director compensation and do not, by themselves, indicate insider buying or selling sentiment. The dual acquisition/disposition lines are consistent with conversion/settlement of the derivative award into common stock.